{
    "clinical_study": {
        "@rank": "141054", 
        "arm_group": {
            "arm_group_label": "Arm A", 
            "arm_group_type": "Experimental", 
            "description": "All patients with MPNST will continue everolimus 10 mg daily and bevacizumab 10 mg/kg dose every 14 days"
        }, 
        "brief_summary": {
            "textblock": "To determine the clinical response rate of everolimus in combination with bevacizumab for\n      patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated\n      malignant peripheral nerve sheath tumor (MPNST). To evaluate the toxicity and safety of\n      everolimus in combination with bevacizumab in individuals with MPNST"
        }, 
        "brief_title": "Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Malignant Peripheral Nerve Sheath Tumors", 
            "MPNST", 
            "Sarcoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neurofibromatosis 1", 
                "Neurofibromatoses", 
                "Nerve Sheath Neoplasms", 
                "Neurofibrosarcoma", 
                "Neurilemmoma", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients 18 or older\n\n          -  Unresectable or metastatic sporadic or NF1 associated high-grade MPNST\n\n          -  Experienced progression after one or more prior regimens of cytotoxic   chemotherapy\n\n          -  Patients must be able to swallow tablets\n\n          -  Patients must have measurable disease, defined as at least one tumor that is\n             measurable\n\n          -  Patients who develop a recurrence or progression (WHO criteria) of an MPNST in a\n             previously radiated field may be enrolled if it has been at least 4 weeks  since the\n             last dose of radiation therapy\n\n          -  Patients must have recovered from the toxic effects of all prior therapy before\n             entering this study\n\n          -  Adequate organ function\n\n          -  ECOG performance status of 0, 1, or 2\n\n          -  Patents who received an anthracycline prior to enrollment must have an ejection\n             fraction \u2265 50%\n\n          -  Subjects of childbearing potential requires acceptable form of birth control\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Patients currently receiving anticancer therapies or who have received anticancer\n             therapies within 3 weeks of the start of study drug or patients receiving prior\n             treatment with investigational drugs 4 weeks of the start of study drug\n\n          -  Patients may not be currently receiving strong inhibitors of CYP3A4, and may not have\n             received these medications within 1 week of entry\n\n          -  Prior radiotherapy within 4 weeks of the start of study drug\n\n          -  Patients who have had a major surgery or significant traumatic injury within 4 weeks\n             of start of study drug,\n\n          -  Patients who have not recovered from the side effects of any major surgery\n\n          -  Patients that may require major surgery during the course of the study\n\n          -  Less than 7 days have passed from core biopsies or other minor surgical procedures\n             excluding placement of a vascular access device\n\n          -  Patients receiving chronic, systemic treatment with corticosteroids or another\n             immunosuppressive agent(Topical or inhaled corticosteroids are allowed)\n\n          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to\n             require glucocorticoids for brain or leptomeningeal metastases\n\n          -  Other malignancies within the past 3 years except for adequately treated carcinoma of\n             the cervix or basal or squamous cell carcinomas of the skin\n\n          -  Patients who have any severe and/or uncontrolled medical conditions or other\n             conditions that could affect their participation in the study\n\n          -  Female patients who are pregnant or breast feeding\n\n          -  Patients who have received prior treatment with an mTOR inhibitor or bevacizumab\n\n          -  Patients with known hypersensitivity to rapamycins\n\n          -  concurrent use of anti-coagulant drugs\n\n          -  Patients using Seville orange, star fruit, grapefruit and their juices, and St.\n             John's Wort\n\n          -  Patients taking enzyme inducing anticonvulsants"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661283", 
            "org_study_id": "SARC016"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "10 mg tablet once daily", 
                "intervention_name": "everolimus", 
                "intervention_type": "Drug", 
                "other_name": "Afinitor, everolimus"
            }, 
            {
                "arm_group_label": "Arm A", 
                "description": "10 mg/kg dose every 14 days", 
                "intervention_name": "bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "MPNST", 
            "malignant peripheral nerve sheath tumors", 
            "RAD001", 
            "Everolimus", 
            "Bevacizumab", 
            "Sarcoma", 
            "Avastin", 
            "mTOR inhibitor"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "link": {
            "description": "SARC Website", 
            "url": "http://www.sarctrials.org"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-0024"
                    }, 
                    "name": "University of Alabama at Birmingham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington D.C.", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Children's National Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Ann and Robert Lurie Children's Hospital of Chicago"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "University of Iowa"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21218"
                    }, 
                    "name": "Johns Hopkins"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892-1101"
                    }, 
                    "name": "National Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63130"
                    }, 
                    "name": "Washington University in St. Louis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45229-3039"
                    }, 
                    "name": "Cincinnati Children's Hospital Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19106"
                    }, 
                    "name": "Pennsylvania Oncology Hematology Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Children's Hospital of Philadelphia"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors", 
        "overall_official": {
            "affiliation": "National Cancer Institute (NCI)", 
            "last_name": "Brigitte C. Widemann, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of lesions for progression or response via Who criteria", 
            "safety_issue": "No", 
            "time_frame": "great than or equal to 4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661283"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sarcoma Alliance for Research through Collaboration", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Novartis Pharmaceuticals", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Genentech", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Department of Defense", 
                    "agency_class": "U.S. Fed"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sarcoma Alliance for Research through Collaboration", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}